ABX-002 Enters Bipolar Depression With Novel Mechanism but No Controlled Evidence to Validate It

Autobahn Initiates Phase 2 Trial for ABX-002 in Bipolar Depression

Autobahn Therapeutics has initiated a Phase 2 open-label clinical trial for ABX-002, a highly potent, oral, thyroid hormone beta receptor (TRβ) selective agonist, as an adjunctive treatment for adults with bipolar depression. The trial aims to establish biological and clinical proof-of-concept, utilizing neuroimaging and clinical endpoints. Topline data from this study is anticipated in the second half of 2025. This expands the company's depression program, which also includes the AMPLIFY Phase 2 trial for major depressive disorder, setting up a transformational year for Autobahn.

• The Phase 2 open-label trial is designed to enroll 30 adult patients experiencing depressive episodes associated with bipolar I and bipolar II disorder. The study will utilize neuroimaging assessments and validated clinical scales to evaluate changes in metabolites linked to brain energy metabolism and improvements in depressive symptoms.
• Primary endpoints for the trial will assess the correlation of change from baseline of nucleoside triphosphate (NTP) and phosphocreatine (PCr) in the brain, as determined by phosphorus magnetic resonance spectroscopy imaging (31P-MRS), with the percent change in the Hamilton Depression Rating Scale-17 (HAMD-17) over six weeks of dosing.
• This trial initiation significantly expands Autobahn's clinical depression program, complementing the ongoing AMPLIFY Phase 2 trial for major depressive disorder (MDD). With two Phase 2 trial readouts expected in the second half of 2025, the company anticipates a transformational year in addressing unmet needs for patients living with depression worldwide.

Addressing the Persistent Unmet Needs in Bipolar Depression

Recent literature highlights that bipolar depression remains an area of significant therapeutic challenge, with persistent gaps in both definitional clarity and effective treatment options for specific patient subgroups. Research published between 2023 and 2026 identifies several distinct populations and clinical scenarios where current standard-of-care approaches fall short.

• Treatment-resistant bipolar depression (TRBD): Patients who fail to respond to conventional psychopharmacology represent a core unmet need. The absence of a standardized definition of treatment resistance — including ambiguity around the frequency, duration, and number of medication failures — undermines both clinical decision-making and the consistency of research outcomes across TRBD subtypes.

• Patients with comorbid insulin resistance: Insulin resistance has been identified as a factor that shifts responsive bipolar disorder toward a treatment-resistant course. A clinical trial demonstrated that reversal of insulin resistance via metformin improved clinical and functional outcomes in TRBD, with a predictive model using BMI and homeostatic model assessment-insulin resistance (HOMA-IR) achieving an area under the receiver operating curve of 0.79 for identifying patients likely to convert to insulin sensitivity.

• Patients at risk of manic switching or suicidality during antidepressant treatment: Antidepressant use in bipolar depression carries risks of switching to manic-mixed episodes and worsening of internal tension, psychomotor agitation, and suicide risk. A retrospective study of 59 TR-BD patients treated with intravenous ketamine (mean dose 0.8 mg/kg) showed significant reductions in Montgomery-Åsberg Depression Rating Scale (MADRS) global scores — including the Internal Tension, Reduced Sleep, and Suicidal Ideation items — from the second week onward, with no manic switches observed during the observation period.

• Pediatric populations with bipolar depression: Youth with bipolar depression represent an underserved group, with ketamine demonstrating tolerability and symptom improvement in this population, and psilocybin showing early promise in fostering emotional processing, though ethical considerations around dissociative and hallucinogenic therapies in pediatric patients remain a key barrier to broader adoption.

• Real-world patients managed on quetiapine extended-release: Post-marketing surveillance of quetiapine fumarate extended-release tablets (Bipresso® 50 mg and 150 mg) across 345 patients over 12 weeks confirmed real-world efficacy, with MADRS total score reductions of -7.3, -12.2, and -16.8 points at 4, 8, and 12 weeks, respectively. Adverse drug reactions occurred in 32.17% of patients, with somnolence (15.94%) as the most common, and "longer time since onset of the first episode" and "presence of complications" identified as significant risk factors — underscoring the need for better tolerability profiling in real-world settings.

TRβ Agonism: A New Frontier in Bipolar Depression?

The initiation of a Phase 2 trial for ABX-002 in bipolar depression signals a strategic move by Autobahn Therapeutics into a challenging but high-need therapeutic area. This oral, highly potent TRβ selective agonist offers a novel mechanistic approach, aiming to leverage the therapeutic benefits of thyroid hormones while minimizing the cardiac side effects often associated with non-selective agents. The scientific rationale for targeting TRβ in depression is compelling, given the emerging understanding of brain energy metabolism and neuroplasticity in mood disorders. Studies indicate that mitochondrial dysfunction is implicated in depression, and thyroid hormones play a crucial role in maintaining cellular homeostasis and promoting mitochondrial biogenesis.

However, the path forward is not without its complexities. While the concept of thyroid hormone augmentation in depression is not entirely new, previous research has yielded mixed results, with some studies showing efficacy but others failing to demonstrate significant differences. This underscores the importance of ABX-002's TRβ selectivity, which aims to provide a more targeted and potentially safer intervention. The trial's design, incorporating neuroimaging and biological endpoints, is a critical strategic element. By assessing target engagement with brain bioenergetics, Autobahn seeks to establish early proof-of-concept, which could be instrumental in de-risking subsequent development phases. This approach aligns with modern drug development paradigms that emphasize understanding mechanism of action in vivo.

• Key considerations for this program include:

• Demonstrating robust efficacy: Overcoming the historical inconsistencies of thyroid hormone augmentation in depression will be crucial.

• Managing potential off-target effects: Despite selectivity, the intricate nature of TRβ interactions with coregulators necessitates vigilant safety monitoring.

• Defining the patient population: Identifying which subset of bipolar depression patients might benefit most from this specific mechanism could optimize future trial designs.

Ultimately, the success of ABX-002 could not only provide a much-needed adjunctive therapy for bipolar depression but also validate TRβ agonism as a broader therapeutic strategy for CNS disorders, potentially reshaping how we approach conditions linked to altered brain energy metabolism and neuroplasticity. The anticipated topline data in late 2025 will be a pivotal moment for this innovative program.